Gale G R, Atkins L M, Smith A B, Walker E M, Fody E P
Toxicol Appl Pharmacol. 1986 Feb;82(2):368-77. doi: 10.1016/0041-008x(86)90214-0.
Acetaminophen (ACM) administration to mice of the (C57BL/6 X DBA/2)F1 strain produced a typical hepatic centrilobular necrosis similar to that observed in rodents and humans. To determine the effects of this drug-induced necrosis on cadmium (Cd) metabolism, mice were given a sublethal dose of CdCl2 . 2.5 H2O containing 109CdCl2 and maintained for a period of time sufficient for Cd-metallothionein (Cd-MT) to be synthesized and distributed. Subsequent administration of ACM ip or po evoked a marked redistribution of Cd from livers to kidneys of mice, and increased the amount of Cd excreted in urine and feces. There were only minimal or no effects on Cd concentrations in other organs assessed. The effect of ACM on Cd redistribution was antagonized by administration of cysteine, a glutathione precursor, and was enhanced by pretreatment with phenobarbital, a potent inducer of the cytochrome P-450 mixed-function oxidase system. Pretreatment of mice with ACM 6 or 24 hr prior to Cd administration caused aberrations of the normal Cd distribution pattern, but no effect was noted when Cd administration was delayed for 48 hr after ACM injection, indicating recovery of the mechanisms of Cd-MT synthesis and sequestration. Sephadex G-75 gel filtration chromatography of serum from ACM-treated mice showed that most of the Cd was associated with high-molecular-weight proteins, and only a minor portion was present as Cd-MT. Cd excreted in urine was predominantly in a low-molecular-weight form, but there was evidence of two minor components of higher molecular weight, neither of which eluted as Cd-MT. Cd excreted in feces was insoluble following homogenization in 0.25 M sucrose solution. Cd in livers and kidneys of ACM-treated mice eluted as Cd-MT. It was concluded that persons who have a moderately high Cd burden may be at risk of Cd nephrotoxicity if they incur hepatic necrosis subsequent to ACM abuse.
给(C57BL/6×DBA/2)F1品系小鼠服用对乙酰氨基酚(ACM)会产生典型的肝小叶中心坏死,类似于在啮齿动物和人类中观察到的情况。为了确定这种药物诱导的坏死对镉(Cd)代谢的影响,给小鼠服用含有109CdCl2的亚致死剂量的CdCl2·2.5H2O,并维持足够长的时间以使镉金属硫蛋白(Cd-MT)合成并分布。随后腹腔注射或口服ACM会引起小鼠肝脏中的Cd明显重新分布到肾脏,并增加尿液和粪便中Cd的排泄量。对评估的其他器官中的Cd浓度只有极小影响或没有影响。ACM对Cd重新分布的影响可通过给予谷胱甘肽前体半胱氨酸来拮抗,而用细胞色素P-450混合功能氧化酶系统的强效诱导剂苯巴比妥预处理可增强这种影响。在给予Cd之前6或24小时用ACM预处理小鼠会导致正常Cd分布模式出现异常,但在ACM注射后延迟48小时给予Cd则未观察到影响,表明Cd-MT合成和螯合机制已恢复。对ACM处理的小鼠血清进行葡聚糖凝胶G-75凝胶过滤层析显示,大部分Cd与高分子量蛋白质结合,只有一小部分以Cd-MT形式存在。尿液中排泄的Cd主要呈低分子量形式,但有证据表明存在两种较高分子量的次要成分,两者均未以Cd-MT形式洗脱。粪便中排泄的Cd在0.25M蔗糖溶液中匀浆后不溶。ACM处理的小鼠肝脏和肾脏中的Cd以Cd-MT形式洗脱。得出的结论是,如果因滥用ACM而发生肝坏死,Cd负荷适度较高的人可能有Cd肾毒性风险。